Review

Silent clues in blood: Proteomic approach for Alzheimer's disease.

Adriele Rebeca Vieira da Silva Renata Santos Vieira da Conceição Carla Mariana da Silva Medeiros Michely da Silva Sousa J. R. de Jesus C. A. Lopes

2026 · International review of neurobiology · Vol 191, pp. 345-402 · 0 citations

Medicine

TL;DR

Current research focused on blood protein biomarkers may reveal key clues for fully understanding the etiology of AD, enabling earlier diagnosis and monitoring of its progression, thereby paving the way for research targeting a cure.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Sep 2026

CSF proteomics and machine learning reveal distinct stages across the Alzheimer’s disease continuum

These findings uncover protein signatures that reflect underlying AD biology and provide a foundation for stage-specific biomarkers and therapeutic targeting, with important implications for patient stratification and personalized intervention strategies.

Saima Rathore, E. Dammer, Anantharaman Shantaraman et al. · Molecular Neurodegeneration · 0 citations

Review 2026

Silent clues in blood: Proteomic approach for Alzheimer's disease.

Similar papers

CSF proteomics and machine learning reveal distinct stages across the Alzheimer’s disease continuum

Circulating biochemical signatures of neurodegeneration in Alzheimer's disease.

Blood-based emerging biomarkers in early detection and diagnosis of Alzheimer's disease.

The emerging landscape of circulatory biomarkers in Alzheimer's disease.

Redefining Alzheimer's disease diagnostics in the age of blood-based biomarkers.

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders.